ISIN | LU2207278669 |
---|---|
Valorennummer | 114371863 |
Bloomberg Global ID | |
Fondsname | Kieger Impact Healthcare Fund Class R USD Accumulating |
Fondsanbieter |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Telefon: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
Fondsanbieter | Kieger AG |
Vertreter in der Schweiz |
ACOLIN Fund Services AG Zürich Telefon: +41 44 396 96 96 |
Distributor(en) | |
Anlagekategorie | Aktienfonds |
EFC-Kategorie | |
Anteilskategorie | Accumulation |
Domizilland | Luxemburg |
Konditionen bei der Ausgabe | keine Ausgabekommission und/oder Gebühren zugunsten des Fonds (Ausgabe erfolgt zum Inventarwert) |
Konditionen bei der Rücknahme | Keine Rücknahmekommission und/oder Gebühren zugunsten des Fonds (Rücknahme erfolgt zum Inventarwert) |
Investment-Strategie *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved. |
Besonderheiten |
Aktueller Preis * | 92.92 USD | 05.09.2024 |
---|---|---|
Vorheriger Preis * | 93.00 USD | 04.09.2024 |
52 Wochen Hoch * | 98.37 USD | 28.12.2023 |
52 Wochen Tief * | 79.75 USD | 10.11.2023 |
NAV * | 92.92 USD | 05.09.2024 |
Ausgabepreis * | ||
Rücknahmepreis * | ||
Schlusskurs * | ||
Indikativer Minimalpreis | ||
Fondsvermögen *** | 86'233'989 | |
Anteilsklassevermögen *** | 1'891 | |
Trading Information SIX |
YTD-Performance | -4.77% |
29.12.2023 - 05.09.2024
29.12.2023 05.09.2024 |
---|---|---|
YTD-Performance (in CHF) | -4.40% |
29.12.2023 - 05.09.2024
29.12.2023 05.09.2024 |
1 Monat | +3.08% |
05.08.2024 - 05.09.2024
05.08.2024 05.09.2024 |
3 Monate | -2.27% |
05.06.2024 - 05.09.2024
05.06.2024 05.09.2024 |
6 Monate | -2.38% |
05.03.2024 - 05.09.2024
05.03.2024 05.09.2024 |
1 Jahr | -2.50% |
05.09.2023 - 05.09.2024
05.09.2023 05.09.2024 |
2 Jahre | -7.08% |
06.07.2023 - 05.09.2024
06.07.2023 05.09.2024 |
3 Jahre | - | - |
5 Jahre | - | - |
Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Pacira BioSciences Inc | 3.94% | |
---|---|---|
Penumbra Inc | 3.93% | |
ResMed Inc | 3.92% | |
Sage Therapeutics Inc | 3.89% | |
Hikma Pharmaceuticals PLC | 3.87% | |
Organon & Co Ordinary Shares | 3.84% | |
Intra-Cellular Therapies Inc | 3.83% | |
DexCom Inc | 3.69% | |
Allogene Therapeutics Inc | 3.69% | |
Centene Corp | 3.67% | |
Letzte Daten-Aktualisierung | 30.04.2023 |
TER *** | 2.22% |
---|---|
Datum TER *** | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 2.00% |
Ongoing Charges *** | 1.44% |
SRRI ***
|
|
Datum SRRI *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |